UK-based pharmaceutical company GSK has reported positive outcomes from two Phase III trials of depemokimab for treating ...

A pooled analysis of both trials showed notable reductions from baseline in nasal polyp score (NPS) at 52 weeks and mean nasal obstruction scores (VRS) for over weeks 49-52. GSK said that ...